Zoekresultaten - Steven Coutré

Verfijn jouw resultaten
  1. 1
    Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion.

    Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion. door Jeffrey D. Lifson, Steven Coutré, Erich Huang, E G Engleman

    Gepubliceerd in 1986
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

    The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management door Jason Gotlib, Jan Cools, James Malone, Stanley L. Schrier, D. Gary Gilliland, Steven Coutré

    Gepubliceerd in 2003
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management

    Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management door David Iberri, Bernice Y. Kwong, Laurel A. Stevens, Steven Coutré, Jinah Kim, Jean Sabile, Ranjana H. Advani

    Gepubliceerd in 2016
    Volledige tekst Volledige tekst
    Carta
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p

    Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p door James I. Barnes, Vasu Divi, Adrian Begaye, Russell Wong, Steven Coutré, Douglas K Owens, Jeremy D. Goldhaber‐Fiebert

    Gepubliceerd in 2018
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Treatment advances have not improved the early death rate in acute promyelocytic leukemia

    Treatment advances have not improved the early death rate in acute promyelocytic leukemia door James Scott McClellan, Holbrook E. Kohrt, Steven Coutré, Jason Gotlib, Ravindra Majeti, Ash A. Alizadeh, Bruno C. Medeiros

    Gepubliceerd in 2011
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass

    Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass door Abe DeAnda, Steven Coutré, Marc R. Moon, Conrad Vial, Linda C. Griffin, Veronica S. Law, Masashi Komeda, Lawrence Leung, D. Craig Miller

    Gepubliceerd in 1994
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  7. 7
    A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia

    A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia door Sucha Nand, Megan Othus, John E. Godwin, Cheryl L. Willman, Thomas H. Norwood, Dianna S. Howard, Steven Coutré, Harry P. Erba, Frederick R. Appelbaum

    Gepubliceerd in 2013
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  8. 8
    Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

    Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia door Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutré, Wyndham H. Wilson, Maryalice Stetler‐Stevenson, David J. FitzGerald, Robert J. Lechleider, Ira Pastan

    Gepubliceerd in 2012
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  9. 9
    PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

    PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma door Paul G. Richardson, Robert Schlossman, Melissa Alsina, Donna M. Weber, Steven Coutré, Cristina Gasparetto, Sutapa Mukhopadhyay, Michael S. Ondovik, Md Mahmudul Hasan Khan, Carole Paley, Sagar Lonial

    Gepubliceerd in 2013
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  10. 10
    A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)

    A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535) door Jeffrey E. Lancet, Anna Moseley, Steven Coutré, Daniel J. DeAngelo, Megan Othus, Martin S. Tallman, Mark R. Litzow, Rami S. Komrokji, Harry P. Erba, Frederick R. Appelbaum

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  11. 11
    Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801

    Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 198... door Daniel J. DeAngelo, Daohai Yu, Jeffrey L. Johnson, Steven Coutré, Richard M. Stone, Alison Stopeck, Jon P. Gockerman, Beverly S. Mitchell, Frederick R. Appelbaum, Richard A. Larson

    Gepubliceerd in 2007
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  12. 12
    SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

    SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia door Anjali S. Advani, Shannon McDonough, Steven Coutré, Brent L. Wood, Jerald P. Radich, Martha P. Mims, Margaret O’Donnell, S. Elkins, Michael W. Becker, Megan Othus, Frederick R. Appelbaum

    Gepubliceerd in 2014
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  13. 13
    Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

    Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up door Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Steven Coutré, Wyndham H. Wilson, Maryalice Stetler‐Stevenson, David J. FitzGerald, Linda Santiago, Guozhi Gao, Mark C. Lanasa, Ira Pastan

    Gepubliceerd in 2018
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  14. 14
    Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro

    Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro door Kenro Kusumi, Barbara R. Conway, Sharon C. Cunningham, Amy E. Berson, Christopher H. Evans, Astrid K. N. Iversen, Daniel C. Colvin, Michael V. Gallo, Steven Coutré, Eugene G. Shpaer

    Gepubliceerd in 1992
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  15. 15
    Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all‐<i>trans</i> retinoic acid and arsenic trioxide

    Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all‐<i>trans</i> retinoic acid and arsenic trioxide door David Sanford, Francesco Lo‐Coco, Miguel Á. Sanz, Eros Di Bona, Steven Coutré, Jessica K. Altman, Meir Wetzler, Steven L. Allen, Farhad Ravandi, Hagop M. Kantarjian, Jorge E. Cortés

    Gepubliceerd in 2015
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  16. 16
    Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia

    Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia door Daniel A. Pollyea, James L. Zehnder, Steven Coutré, Jason Gotlib, Leonel Gallegos, Omar Abdel‐Wahab, Peter L. Greenberg, Bing Zhang, Michaela Liedtke, Caroline Berube, Ross L. Levine, Beverly S. Mitchell, Bruno C. Medeiros

    Gepubliceerd in 2012
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  17. 17
    Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia

    Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia door Anjali S. Advani, Holly Gundacker, Olga Sala‐Torra, Jerald P. Radich, Raymond Lai, Marilyn L. Slovak, Jeffrey E. Lancet, Steven Coutré, Robert K. Stuart, Martha P. Mims, Patrick J. Stiff, Frederick R. Appelbaum

    Gepubliceerd in 2010
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  18. 18
    Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

    Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma door Wei-Gang Tong, Rong Chen, William Plunkett, David S. Siegel, Rajni Sinha, R. Donald Harvey, Ashraf Badros, Leslie Popplewell, Steven Coutré, Judith A. Fox, Kristi Mahadocon, Tianling Chen, Peggy Kegley, Ute Hoch, William G. Wierda

    Gepubliceerd in 2010
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  19. 19
    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy door Steven Coutré, Michael Y. Choi, Richard R. Furman, Herbert Eradat, Leonard T. Heffner, Jeffrey A. Jones, Brenda Chyla, Lang Zhou, Suresh Agarwal, Tina Waskiewicz, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, William G. Wierda, Matthew S. Davids

    Gepubliceerd in 2018
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  20. 20
    A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

    A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL) door Brad S. Kahl, Stephen E. Spurgeon, Richard R. Furman, Ian W. Flinn, Steven Coutré, Jennifer R. Brown, Don M. Benson, John C. Byrd, Sissy Peterman, Yoonjin Cho, Albert S. Yu, Wayne R. Godfrey, Nina D. Wagner‐Johnston

    Gepubliceerd in 2014
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: